BioAge Raises $90M in Series C Funding

BioAge Labs

BioAge Labs, Inc., a Richmond, CA-based biotechnology company developing medicines to treat aging and aging-related diseases, raised $90m in Series C financing.

The round was co-led by Andreessen Horowitz and serial entrepreneur Elad Gil, with participation from new investors Kaiser Foundation Hospitals, AARP Foundation (through the RockCreek Impact Fund) and Phi-X Capital, the fund of genomics entrepreneur Mostafa Ronaghi, among others, as well as current investors Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures, and others.

Proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increase healthspan and lifespan, augment BioAge’s artificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Led by Kristen Fortney, PhD, co-founder and chief executive officer, BioAge is a biotechnology company developing proprietary drugs to treat aging and aging- related diseases. The company leverages a platform that identifies key drug targets by using datasets to identify the molecular drivers of age-related pathology. BioAge’s pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

Separately, the company announced that Paul Rubin, M.D. will lead its clinical development efforts as chief medical officer. Dr. Rubin, a veteran biopharmaceutical drug developer, brings extensive experience from early discovery, late stage development and ultimate drug approvals across a wide variety of therapeutic areas in global geographies. In former roles heading development at Sepracor, GSK and Abbott, Dr. Rubin has been responsible for the clinical development and approval of more than ten products. Prior to BioAge, he was most recently executive vice president, Research and Development for MiRagen and held a similar role at Xoma, two biotechnology companies. Dr. Rubin earned his M.D. at Rush Medical College, Chicago.



Join the discussion